A 19-year-old from British Columbia has made medical history as the first person cured of a rare genetic disorder using a breakthrough technology called prime gene editing. Ty Sperle, a university student from Kelowna, successfully underwent the experimental treatment to eliminate a life-threatening immune condition that had plagued him since childhood.
The landmark achievement, published in the New England Journal of Medicine, marks a major milestone for Prime Medicine, the biotechnology company behind the therapy. By correcting a precise DNA spelling mistake in Sperle’s own cells, the prime gene editing treatment fully restored his immune system, allowing him to live without the daily medications he once needed to survive.
Overcoming Chronic Granulomatous Disease
Diagnosed around the age of five, Sperle suffered from chronic granulomatous disease (CGD). This rare inherited immune deficiency prevents white blood cells from producing the chemicals necessary to kill off harmful microbes. As a result, patients face a severe risk of life-threatening bacterial and fungal infections.
For most of his life, Sperle relied on a strict regimen of daily antibiotics and antifungal drugs to ward off illness. Even ordinary activities like camping posed significant dangers due to bacteria in the woods. While a bone marrow transplant from a healthy donor can cure the disease by wiping out the compromised immune system and building a new one, finding an optimal match is incredibly difficult. Sperle did not have a suitable donor available, leaving him with few conventional options.
How the Prime Gene Editing Treatment Works
To cure the condition, doctors utilized an innovative approach known as prime gene editing. First introduced in 2019 by Broad Institute biochemist David Liu, this CRISPR-based tool functions like a genetic search-and-replace mechanism. Unlike older gene-editing methods that completely sever both strands of DNA—which forces cells to patch the break and can lead to unwanted genetic changes—prime editing rewrites the genetic code without making double-strand breaks.
During the multi-national Phase 1/2 clinical trial, which took place at Montreal’s Sainte-Justine university hospital, medical teams extracted Sperle’s own blood-forming stem cells. In a laboratory setting, they used the prime editing therapy, called PM359, to insert the missing DNA letters and fix the specific mutation causing his disease.
Before the repaired cells were returned to his body, Sperle received myeloablative conditioning, a type of chemotherapy used to clear space in the bone marrow. Once infused back into his bloodstream, the corrected stem cells rapidly multiplied and successfully rebuilt his immune system from the inside out. Because the treatment used his own cells, it eliminated the risk of immune rejection and graft-versus-host disease.
Rapid Recovery and Clinical Success
The clinical data demonstrated remarkable speed and efficacy. Within weeks of receiving the single intravenously administered dose, Sperle’s immune function was completely restored. Tests showed that the necessary microbe-killing activity returned to 58 percent of his neutrophils by day 15, and 66 percent by day 30. This was well above the 20 percent minimum threshold needed for clinical benefit. Furthermore, his body experienced rapid engraftment, occurring almost twice as fast as with other approved gene-editing technologies.
Dr. Stuart Turvey, a pediatric immunologist who treated Sperle for over a decade at BC Children’s Hospital in Vancouver, monitored his long-term recovery. Months of follow-up confirmed that Sperle’s newly edited cells had safely taken over, providing durable immune protection without therapy-linked safety issues. A second patient treated in the trial also showed stable immune function after four months of follow-up.
Future Prospects for Genetic Medicines
Now a second-year science student at the University of British Columbia’s Okanagan campus, Sperle is entirely off his previous medication regimen and can safely enjoy the outdoors. British Columbia Health Minister Josie Osborne praised the successful treatment as a milestone that highlights the power of public healthcare, scientific research, and global collaboration.
Following these early successes, Prime Medicine plans to seek approval from the Food and Drug Administration for the treatment, which has already received Rare Paediatric Drug and Orphan Drug designations. However, the company recently announced it will explore external options for the continued clinical development of PM359 rather than independently advancing its efforts in CGD.
As this technology moves from the laboratory to human patients, researchers hope to apply prime gene editing to thousands of other genetic diseases caused by small DNA mutations. The challenge now shifts toward scaling these highly customized cell therapies, expanding manufacturing capacity, and navigating the complexities of healthcare systems so that one-time genetic cures can become widely accessible.
